Andrew W. Roberts, PharmD, PhD
Articles
July 15th 2021
Trends in Medicare Part D Coverage of Generics With Equivalent Brand-Name Drugs
Stacie B. Dusetzina, PhD Juliette Cubanski, PhD Andrew W. Roberts, PharmD, PhD Jack Hoadley, PhD Sarah True, MPH, MSW Leonce Nshuti, MSc Tricia Neuman, ScD
High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug coverage.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: September 19th 2024 | Updated: November 21st 2024
Institute for Value-Based Medicine®: Speakers Use AML Studies to Illustrate Effects of Disparities, Neighborhood Stress on Outcomes
